| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The FASEB Journal, Vol 2, 224-236, Copyright © 1988 by The Federation of American Societies for Experimental Biology
REVIEWS |
HF DeLuca
Department of Biochemistry, University of Wisconsin-Madison 53706.
The discovery in 1919-1924 of vitamin D and its production in skin and foods by UV irradiation led to the elimination of rickets as a major medical problem. The identification and chemical preparation of vitamin D in the next decade provided large quantities of vitamin D to the physician for the treatment of a variety of metabolic bone diseases. Early in the 1960s, little was known about the function of vitamin D in causing mineralization of the skeleton, and hence in preventing the disease rickets in children and osteomalacia in adults. With the application of modern tools of biochemistry came the discovery that vitamin D must first be modified by 25-hydroxylation in the liver followed by 1 alpha-hydroxylation in the kidney to produce the vitamin D hormone 1 alpha,25-dihydroxyvitamin D3 [1,25-(OH)2D3]. This process is strongly feedback-regulated and is one of the major endocrine systems regulating plasma calcium and phosphorus concentrations. Furthermore, it is a major endocrine system regulating bone mass and state. With the chemical synthesis of 1,25-(OH)2D3 and many of its analogs has come the possibility of treating a number of metabolic bone diseases not previously managed adequately, such as vitamin D-resistant rickets, hypoparathyroidism, renal osteodystrophy, and osteoporosis. By using 1,25-(OH)2D3, considerable work has been carried out to understand how this hormone facilitates calcium transport across the intestinal membrane. Modern work is described on the molecular mechanism of action of the vitamin D hormone in eliciting the cellular responses that result in mineral homeostasis. The possible use of the vitamin D analogs to bring about differentiation of myelocytic-type leukemias and in the treatment of psoriasis has been an important new development. This paper will thus be a blend of basic science of the vitamin D system and the application of that information to the treatment of disease.
This article has been cited by other articles:
|
|
 |
|
  M. T. Hannan, H. J. Litman, A. B. Araujo, C. E. McLennan, R. R. McLean, J. B. McKinlay, T. C. Chen, and M. F. Holick Serum 25-Hydroxyvitamin D and Bone Mineral Density in a Racially and Ethnically Diverse Group of Men J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 40 - 46. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ehrchen, L. Helming, G. Varga, B. Pasche, K. Loser, M. Gunzer, C. Sunderkotter, C. Sorg, J. Roth, and A. Lengeling Vitamin D receptor signaling contributes to susceptibility to infection with Leishmania major FASEB J, October 1, 2007; 21(12): 3208 - 3218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Meyer, L. A. Zella, R. D. Nerenz, and J. W. Pike Characterizing Early Events Associated with the Activation of Target Genes by 1,25-Dihydroxyvitamin D3 in Mouse Kidney and Intestine in Vivo J. Biol. Chem., August 3, 2007; 282(31): 22344 - 22352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Meyer, M. Watanuki, S. Kim, N. K. Shevde, and J. W. Pike The Human Transient Receptor Potential Vanilloid Type 6 Distal Promoter Contains Multiple Vitamin D Receptor Binding Sites that Mediate Activation by 1,25-Dihydroxyvitamin D3 in Intestinal Cells Mol. Endocrinol., June 1, 2006; 20(6): 1447 - 1461. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Helming, J. Bose, J. Ehrchen, S. Schiebe, T. Frahm, R. Geffers, M. Probst-Kepper, R. Balling, and A. Lengeling 1{alpha},25-dihydroxyvitamin D3 is a potent suppressor of interferon {gamma}-mediated macrophage activation Blood, December 15, 2005; 106(13): 4351 - 4358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. G. Bolt, W. Liu, G. Qiao, J. Kong, W. Zheng, T. Krausz, G. Cs-Szabo, M. D. Sitrin, and Y. C. Li Critical role of vitamin D in sulfate homeostasis: regulation of the sodium-sulfate cotransporter by 1,25-dihydroxyvitamin D3 Am J Physiol Endocrinol Metab, October 1, 2004; 287(4): E744 - E749. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. N. Evans, J. N. Bulmer, M. D. Kilby, and M. Hewison Vitamin D and Placental-Decidual Function Reproductive Sciences, July 1, 2004; 11(5): 263 - 271. [Abstract] [PDF]
|
|
|
|
|
|
T. Yamasaki, S. Izumi, H. Ide, and Y. Ohyama Identification of a Novel Rat Microsomal Vitamin D3 25-Hydroxylase J. Biol. Chem., May 28, 2004; 279(22): 22848 - 22856. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kuhlmann, C. S. Haas, M.-L. Gross, U. Reulbach, M. Holzinger, U. Schwarz, E. Ritz, and K. Amann 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat Am J Physiol Renal Physiol, March 1, 2004; 286(3): F526 - F533. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. M. Weaver 2003 W. O. Atwater Memorial Lecture: Defining Nutrient Requirements from a Perspective of Bone-Related Nutrients J. Nutr., December 1, 2003; 133(12): 4063 - 4066. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Papadimitropoulos, G. Wells, B. Shea, W. Gillespie, B. Weaver, N. Zytaruk, A. Cranney, J. Adachi, P. Tugwell, R. Josse, et al. VIII: Meta-Analysis of the Efficacy of Vitamin D Treatment in Preventing Osteoporosis in Postmenopausal Women Endocr. Rev., August 1, 2002; 23(4): 560 - 569. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Guzey, S. Kitada, and J. C. Reed Apoptosis Induction by 1{alpha},25-Dihydroxyvitamin D3 in Prostate Cancer Mol. Cancer Ther., July 1, 2002; 1(9): 667 - 677. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. K. O. Siaw and M. R. Walters 1,25-Dihydroxyvitamin D-stimulated calmodulin binding proteins: a sustained effect on distal tubules Am J Physiol Renal Physiol, January 1, 2002; 282(1): F77 - F84. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Lips Vitamin D Deficiency and Secondary Hyperparathyroidism in the Elderly: Consequences for Bone Loss and Fractures and Therapeutic Implications Endocr. Rev., August 1, 2001; 22(4): 477 - 501. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Cantorna Vitamin D and Autoimmunity: Is Vitamin D Status an Environmental Factor Affecting Autoimmune Disease Prevalence? Experimental Biology and Medicine, March 1, 2000; 223(3): 230 - 233. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Lipkin and H. L. Newmark Vitamin D, Calcium and Prevention of Breast Cancer: A Review J. Am. Coll. Nutr., October 1, 1999; 18(90005): 392S - 397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Shinki, Y. Ueno, H. F. DeLuca, and T. Suda Calcitonin is a major regulator for the expression of renal 25-hydroxyvitamin D3-1alpha -hydroxylase gene in normocalcemic rats PNAS, July 6, 1999; 96(14): 8253 - 8258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. C. Li, M. Amling, A. E. Pirro, M. Priemel, J. Meuse, R. Baron, G. Delling, and M. B. Demay Normalization of Mineral Ion Homeostasis by Dietary Means Prevents Hyperparathyroidism, Rickets, and Osteomalacia, But Not Alopecia in Vitamin D Receptor-Ablated Mice Endocrinology, October 1, 1998; 139(10): 4391 - 4396. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Armbrecht, T. L. Hodam, M. A. Boltz, N. C. Partridge, A. J. Brown, and V. B. Kumar Induction of the Vitamin D 24-Hydroxylase (CYP24) by 1,25-Dihydroxyvitamin D3 Is Regulated by Parathyroid Hormone in UMR106 Osteoblastic Cells Endocrinology, August 1, 1998; 139(8): 3375 - 3381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Shinki, H. Shimada, S. Wakino, H. Anazawa, M. Hayashi, T. Saruta, H. F. DeLuca, and T. Suda Cloning and expression of rat 25-hydroxyvitamin D3-1alpha -hydroxylase cDNA PNAS, November 25, 1997; 94(24): 12920 - 12925. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Jehan and H. F. DeLuca Cloning and characterization of the mouse vitamin D receptor promoter PNAS, September 16, 1997; 94(19): 10138 - 10143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Akeno, S. Saikatsu, T. Kawane, and N. Horiuchi Mouse Vitamin D-24-Hydroxylase: Molecular Cloning, Tissue Distribution, and Transcriptional Regulation by 1{alpha},25-Dihydroxyvitamin D3 Endocrinology, June 1, 1997; 138(6): 2233 - 2240. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. C. Li, C. Bergwitz, H. Juppner, and M. B. Demay Cloning and Characterization of the Vitamin D Receptor from Xenopus laevis Endocrinology, June 1, 1997; 138(6): 2347 - 2353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ohyama, K. Ozono, M. Uchida, M. Yoshimura, T. Shinki, T. Suda, and O. Yamamoto Functional Assessment of Two Vitamin D-responsive Elements in the Rat 25-Hydroxyvitamin D3 24-Hydroxylase Gene J. Biol. Chem., November 29, 1996; 271(48): 30381 - 30385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bhatia, J. B. Kirkland, and K. A. Meckling-Gill Monocytic Differentiation of Acute Promyelocytic Leukemia Cells in Response to 1,25-Dihydroxyvitamin D[IMAGE] Is Independent of Nuclear Receptor Binding J. Biol. Chem., July 7, 1995; 270(27): 15962 - 15965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Zierold, H. M. Darwish, and H. F. DeLuca Two Vitamin D Response Elements Function in the Rat 1,25-Dihydroxyvitamin D 24-Hydroxylase Promoter J. Biol. Chem., January 27, 1995; 270(4): 1675 - 1678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Morelli, C. Buitrago, G. Vazquez, A. R. De Boland, and R. Boland Involvement of Tyrosine Kinase Activity in 1alpha ,25(OH)2-vitamin D3 Signal Transduction in Skeletal Muscle Cells J. Biol. Chem., November 10, 2000; 275(46): 36021 - 36028. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Guzey, S. Takayama, and J. C. Reed BAG1L Enhances Trans-activation Function of the Vitamin D Receptor J. Biol. Chem., December 22, 2000; 275(52): 40749 - 40756. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
